The phase I trials of venglustat demonstrated successful target engagement (ClinicalTrials.gov Identifier: NCT01674036 and NCT01710826), however the phase II trial failed to show a benefit, with patients with GBA1 mutations exhibiting a decline in motor function in PD (ClinicalTrials.gov Identifier: NCT02906020). This evidence concerns the gene GBA1 and Parkinson disease.